New CAR-T therapy aims to stop High-Risk lymphoma early

NCT ID NCT07569965

Not yet recruiting Disease control Sponsor: Miltenyi Biomedicine GmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a CAR-T cell therapy called zamtocabtagene autoleucel as a first-line consolidation treatment for people with high-risk mantle cell lymphoma. About 52 participants will receive the therapy after standard chemotherapy. The main goal is to see how long they live without the cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zamtocabtagene autoleucel (CAR-T cell therapy)
What this could lead to: If successful, this could offer a more effective first-line treatment option for people with high-risk mantle cell lymphoma, potentially delaying or preventing relapse.
What could go wrong: This is an early Phase 2 trial with only 52 participants, so results may not apply to all patients. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm mantle cell lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA (MCL)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.